תאריך: 18/09/2019 - 20/09/2019
Chairpersons: Ofir Avizohar Rambam Health Care Campus, Israel, Hagai Tavori Oregon Health & Science University, USA
New Opportunities to Reduce Residual Risk Beyond Statin Therapy
New Opportunities to Reduce Residual Risk Beyond Statin TherapyCraig Granowitz
Amarin Pharma Inc. NJ, USA
NatanzonStatin Therapy Among Chronic Kidney Disease Patients Presenting with Acute Coronary Syndrome
NatanzonStatin Therapy Among Chronic Kidney Disease Patients Presenting with Acute Coronary SyndromeSharon Shalom Natanzon
Sheba Medical Center, Israel
Applying asntisense Technology to treat chylomicronemia and high Lp(a)
Applying asntisense Technology to treat chylomicronemia and high Lp(a)Dov Gavish
Wolfson Medical Center ,Israel
Further analysis of recent PCSK9i Mega studies: Implications for clinical use
Further analysis of recent PCSK9i Mega studies: Implications for clinical useGabizon Itzhak
Ben-Gurion University of the Negev ,Israel
Innovation in CVD &T2D treatments from guidelines to clinical practice
Innovation in CVD &T2D treatments from guidelines to clinical practiceRonen Durst
Hadassah Hebrew University Medical Center, Israel
